SCHEMBL15041310

SCHEMBL15041310

CN1CCCC(Oc2ccc(Nc3ncc4cc(C(=O)C5CCOCC5)c(=O)n(C5CSc6ccccc6C5)c4n3)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 13/20 0.40
CCND1 P24385 13/20 0.40
CDK2 P24941 11/20 0.40
CCNA2 P20248 10/20 0.40
FGFR1 P11362 8/20 0.40
FGFR2 P21802 7/20 0.40
FGFR4 P22455 7/20 0.40
FGFR3 P22607 7/20 0.40
CCNE1 P24864 4/20 0.39
CDK6 Q00534 3/20 0.39
CDK1 P06493 2/20 0.39
CCNB1 P14635 2/20 0.39
PIK3CD O00329 1/20 0.39
PRKAB2 O43741 1/20 0.39
NUAK1 O60285 1/20 0.39
CCNT1 O60563 1/20 0.39
ABL1 P00519 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035312 0.93 CDK4 (0.39) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041579 0.86 CAMK2D (0.42) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041304 0.85 TNK2 (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041356 0.84 TNK2 (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041293 0.82 CAMK2D (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15035467 0.79 CAMK2D (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15035426 0.79 TNK2 (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041554 0.78 CDK4 (0.42) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15035527 0.77 TNK2 (0.40) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL15041808 0.77 CDK4 (0.41) CDK4CCND1CDK2CCNA2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CCND1 2153/4885CDK2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.